---
figid: PMC3733021__fimmu-04-00221-g001
figlink: /pmc/articles/PMC3733021/figure/F1/
number: F1
caption: (A) Schematic diagram of the ZFN, TALEN, and CRISPR/Cas9 genome editing tools.
  (B) Inhibition of T-cell activation by immune checkpoint receptors and downstream
  signaling proteins. Several co-inhibitory receptors (PD-1, BTLA, and LAIR-1) inhibit
  T-cell signaling by recruiting the SHP-1 and/or SHP-2 tyrosine phosphatases at proximity
  of the TCR signaling complex via ITIMs and ITSMs. This results in the dephosphorylation
  of proximal kinases downstream of TCR triggering. In addition PD-1 ligation was
  shown to induce increased expression of the Cbl-b E3 ubiquitin ligase, which targets
  signaling molecules for degradation. Activation of the CD200R leads to the recruitment
  of DOK2 and RasGAP to its intra-cellular domain, resulting in the inhibition of
  downstream MAP kinases. The adenosine receptor 2A and PGE2 receptors EP2 and EP4
  modulate T-cell activation through mobilization of the cAMP-PKAI-CSK pathway. CSK
  phosphorylates the inhibitory C-terminal tyrosine residue of Src kinases and negatively
  regulates TCR signaling. A2AR, adenosine A2a receptor; APC, antigen-presenting cell;
  BTLA-4, B- and T-lymphocyte attenuator; Cbl-b, casitas B-cell lymphoma; CTL, cytotoxic
  T-lymphocyte; DOK-1/2, docking protein 1/2; EP2/4, prostaglandin E receptor 2/4;
  Erk, extra-cellular signal regulated kinases; ITIM, immunoreceptor tyrosine-based
  inhibition motif; ITSM, immunoreceptor tyrosine-based switch motif; GPCR, G-protein
  coupled receptor; LAG-3, lymphocyte-activation gene 3; LAIR-1, leukocyte-associated
  immunoglobulin-like receptor 1; Lck, lymphocyte-specific protein tyrosine kinase;
  MHC1, major histocompatibility complex class 1; PD-1, programed death receptor 1;
  PD1-L1, programed death receptor 1-ligand 1; SHP-1, Src homology 2 domain containing
  protein tyrosine phosphatase; TCR, T-cell receptor; TIGIT, T-cell immunoreceptor
  with Ig and ITIM domains; TIM-3, T-cell immunoglobulin domain and mucin domain 3.
pmcid: PMC3733021
papertitle: 'Beyond the Antigen Receptor: Editing the Genome of T-Cells for Cancer
  Adoptive Cellular Therapies.'
reftext: Angharad Lloyd, et al. Front Immunol. 2013;4:221.
pmc_ranked_result_index: '133396'
pathway_score: 0.9541649
filename: fimmu-04-00221-g001.jpg
figtitle: Schematic diagram of the ZFN, TALEN, and CRISPR/Cas9 genome editing tools
year: '2013'
organisms:
- Homo sapiens
ndex: 9c2e8ff2-dedc-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3733021__fimmu-04-00221-g001.html
  '@type': Dataset
  description: (A) Schematic diagram of the ZFN, TALEN, and CRISPR/Cas9 genome editing
    tools. (B) Inhibition of T-cell activation by immune checkpoint receptors and
    downstream signaling proteins. Several co-inhibitory receptors (PD-1, BTLA, and
    LAIR-1) inhibit T-cell signaling by recruiting the SHP-1 and/or SHP-2 tyrosine
    phosphatases at proximity of the TCR signaling complex via ITIMs and ITSMs. This
    results in the dephosphorylation of proximal kinases downstream of TCR triggering.
    In addition PD-1 ligation was shown to induce increased expression of the Cbl-b
    E3 ubiquitin ligase, which targets signaling molecules for degradation. Activation
    of the CD200R leads to the recruitment of DOK2 and RasGAP to its intra-cellular
    domain, resulting in the inhibition of downstream MAP kinases. The adenosine receptor
    2A and PGE2 receptors EP2 and EP4 modulate T-cell activation through mobilization
    of the cAMP-PKAI-CSK pathway. CSK phosphorylates the inhibitory C-terminal tyrosine
    residue of Src kinases and negatively regulates TCR signaling. A2AR, adenosine
    A2a receptor; APC, antigen-presenting cell; BTLA-4, B- and T-lymphocyte attenuator;
    Cbl-b, casitas B-cell lymphoma; CTL, cytotoxic T-lymphocyte; DOK-1/2, docking
    protein 1/2; EP2/4, prostaglandin E receptor 2/4; Erk, extra-cellular signal regulated
    kinases; ITIM, immunoreceptor tyrosine-based inhibition motif; ITSM, immunoreceptor
    tyrosine-based switch motif; GPCR, G-protein coupled receptor; LAG-3, lymphocyte-activation
    gene 3; LAIR-1, leukocyte-associated immunoglobulin-like receptor 1; Lck, lymphocyte-specific
    protein tyrosine kinase; MHC1, major histocompatibility complex class 1; PD-1,
    programed death receptor 1; PD1-L1, programed death receptor 1-ligand 1; SHP-1,
    Src homology 2 domain containing protein tyrosine phosphatase; TCR, T-cell receptor;
    TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TIM-3, T-cell immunoglobulin
    domain and mucin domain 3.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TIGIT
  - CD3E
  - PTPN11
  - CD3D
  - TRB
  - PTPN6
  - DOK2
  - CD247
  - CD200R1
  - APC
  - PDCD1
  - CSK
  - TRG
  - BTLA
  - CD8B
  - LAIR1
  - TRD
  - TRA
  - LAG3
  - NMUR1
  - CD8A
  - CD3G
  - DOK1
  - adenosine
  - Phosphate
  - PGE2
genes:
- word: PD-1,BTLA,LAIR-1,TIGIT,LAG-3,TIM3)
  symbol: TIGIT
  source: hgnc_symbol
  hgnc_symbol: TIGIT
  entrez: '201633'
- word: CD3
  symbol: CD3
  source: bioentities_symbol
  hgnc_symbol: CD3E
  entrez: '916'
- word: SHP-1/2
  symbol: SHP-2
  source: hgnc_alias_symbol
  hgnc_symbol: PTPN11
  entrez: '5781'
- word: CD3
  symbol: CD3
  source: bioentities_symbol
  hgnc_symbol: CD3D
  entrez: '915'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: SHP-1/2
  symbol: SHP-1
  source: hgnc_alias_symbol
  hgnc_symbol: PTPN6
  entrez: '5777'
- word: DOK-1/2
  symbol: Dok-2
  source: hgnc_alias_symbol
  hgnc_symbol: DOK2
  entrez: '9046'
- word: CD3
  symbol: CD3
  source: bioentities_symbol
  hgnc_symbol: CD247
  entrez: '919'
- word: CD200R
  symbol: CD200R
  source: hgnc_alias_symbol
  hgnc_symbol: CD200R1
  entrez: '131450'
- word: APC
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: PD-1,BTLA,LAIR-1,TIGIT,LAG-3,TIM3)
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: CSK
  symbol: CSK
  source: hgnc_symbol
  hgnc_symbol: CSK
  entrez: '1445'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
- word: PD-1,BTLA,LAIR-1,TIGIT,LAG-3,TIM3)
  symbol: BTLA
  source: hgnc_symbol
  hgnc_symbol: BTLA
  entrez: '151888'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: LAIR-1,
  symbol: LAIR1
  source: hgnc_symbol
  hgnc_symbol: LAIR1
  entrez: '3903'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: PD-1,BTLA,LAIR-1,TIGIT,LAG-3,TIM3)
  symbol: LAG3
  source: hgnc_symbol
  hgnc_symbol: LAG3
  entrez: '3902'
- word: GPCR
  symbol: GPC-R
  source: hgnc_alias_symbol
  hgnc_symbol: NMUR1
  entrez: '10316'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: CD3
  symbol: CD3
  source: bioentities_symbol
  hgnc_symbol: CD3G
  entrez: '917'
- word: DOK-1/2
  symbol: DOK1
  source: hgnc_symbol
  hgnc_symbol: DOK1
  entrez: '1796'
chemicals:
- word: adenosine
  source: MESH
  identifier: D000241
- word: Phosphate
  source: MESH
  identifier: D010710
- word: PGE2
  source: MESH
  identifier: D015232
diseases: []
figid_alias: PMC3733021__F1
redirect_from: /figures/PMC3733021__F1
figtype: Figure
---
